Waypoint Wealth Partners Inc. Acquires 3,267 Shares of Johnson & Johnson (NYSE:JNJ)

Waypoint Wealth Partners Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 43.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,820 shares of the company's stock after purchasing an additional 3,267 shares during the quarter. Johnson & Johnson accounts for approximately 0.4% of Waypoint Wealth Partners Inc.'s portfolio, making the stock its 26th largest position. Waypoint Wealth Partners Inc.'s holdings in Johnson & Johnson were worth $1,565,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vinva Investment Management Ltd lifted its position in Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after buying an additional 7,110 shares during the last quarter. Financial Counselors Inc. lifted its position in Johnson & Johnson by 5.3% in the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after buying an additional 9,309 shares during the last quarter. Oregon Pacific Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $949,000. Meridian Investment Counsel Inc. lifted its position in Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock worth $3,667,000 after buying an additional 3,710 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after buying an additional 102,502 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price objective for the company. Bank of America lowered their price objective on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, January 23rd. Leerink Partners lowered their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Finally, Stifel Nicolaus lowered their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Stock Up 2.0 %

JNJ stock traded up $3.27 during midday trading on Friday, hitting $162.95. The stock had a trading volume of 6,695,360 shares, compared to its average volume of 8,885,373. The firm has a market cap of $392.32 billion, a price-to-earnings ratio of 24.49, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The business has a 50-day moving average of $148.61 and a two-hundred day moving average of $155.89. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.29 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.04%. Johnson & Johnson's payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.